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GLUCOSE METABOLISM DISORDERS IN PATIENTS WITH 
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SUMMARY – Glucose metabolism disorders in acutely ill patients include oscillations in pla-
sma glucose concentration outside the range of reference values. These disorders include both hyper-
glycemia and hypoglycemia, regardless of previous diagnosis of diabetes in a particular patient. 
Hyperglycemia is frequent in acute patients due to the increased release of stress hormones such 
as catecholamines and cortisol, but also as an effect of a cascade of proinflammatory cytokines in 
emergencies such as acute coronary syndrome, pulmonary edema, pulmonary embolism, injuries, 
severe infections and sepsis. Hyperglycemia occurs often even in patients in whom diabetes was 
not previously diagnosed, and in diabetic patients requirement for hypoglycemic medication may 
be temporarily increased. Hyperglycemia in cardiac emergencies is associated with more frequent 
adverse major cardiovascular events and worse prognosis. Hypoglycemia occurs seldom in these 
patients, its origin is almost always iatrogenic, and it worsens the patient’s prognosis even more than 
moderate hyperglycemia. Good regulation of glycemia is necessary in the management of these 
patients; therefore plasma glucose determination and close monitoring are obligatory, and therapy 
with short acting insulin should be introduced if plasma glucose concentration exceeds 10 mmol/L, 
regardless of the risk of hypoglycemia. It is also useful to determine the acid-base status and blood 
or urine ketones.
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Introduction
Coronary artery disease (CAD) is the leading 
cause of death and physical inability. So far, many risk 
factors have been established, such as male sex, older 
age, smoking, obesity, physical inactivity, comorbidi-
ties like arterial hypertension, diabetes mellitus, hy-
perlipidemia and hypercoagulable states. All of them 
are leading to advanced stages of atherosclerosis with 
prominent intravascular plaques. Rupture of insta-
ble plaques may lead to consecutive thrombosis and 
stenosis or occlusion of the specific vessel. If collat-
eral blood perfusion is insufficient, some form of acute 
coronary syndrome occurs. 
Despite many advances in the treatment of acute 
coronary syndrome, prevention and appropriate treat-
ment of risk factors remain the best way to prevent 
death and major cardiovascular adverse events1.
Diabetes Mellitus and Coronary Heart Disease
Diabetes mellitus has an important impact on vas-
cular disease. It is a major risk factor for heart attack, 
stroke, and lower extremity vascular disease, and the 
leading cause of blindness and end-stage renal disease. 
It is also a major cause of painful peripheral neuropa-
thy, leading to physical disability2-4. 
About three-quarters of diabetic patients die 
from cardiovascular disease and two-thirds of these 
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die from the manifestations of ischemic heart dis-
ease, promoting coronary artery disease to the lead-
ing cause of morbidity and mortality in patients with 
diabetes mellitus. Patients with type 2 diabetes have 
an equivalent cardiovascular risk to that of a non-dia-
betic patient who has already experienced a coronary 
event5,6. 
Patients with diabetes are more likely to experience 
acute myocardial infarction (AMI) and heart failure, 
and are at a greater risk of dying from an acute car-
diac event than patients without diabetes. These dif-
ferences may be related to the severity and extent of 
coronary heart disease in diabetic patients, the extent 
of left ventricular remodeling, and the presence of sig-
nificant ventricular arrhythmias7-9. 
However, the main reason for increased prehos-
pital, intrahospital and 1-year post-hospital mortality 
in diabetic patients is the development of heart failure 
after AMI. Sudden death and fatal ventricular ar-
rhythmias contribute to a lesser extent to the increased 
mortality rate7. 
Over the past few years, several new methods of 
treating CAD and acute coronary syndrome (ACS) 
have been introduced, but patients with diabetes have 
not enjoyed the same decline in CAD-related mortal-
ity as nondiabetic individuals. Poor prognosis associ-
ated with diabetes after AMI has been observed in 
several studies despite adjustment for age, treatment, 
sex, additional comorbidities, and coronary risk fac-
tors2. 
The negative prognostic implications of diabetes 
apply to patients with different manifestations of ACS, 
including unstable angina, non-ST segment elevation 
AMI (NSTEMI), and ST-segment elevation AMI 
(STEMI). In addition, since patients with diabetes 
who develop ACS appear to sustain worse outcomes 
than those without diabetes, it is important to deter-
mine if they are receiving proven cardiac interventions 
under current practices.
There is also mounting evidence that people with 
coronary heart disease often have undiagnosed type 2 
diabetes, impaired glucose tolerance or impaired fast-
ing glucose, which is indicative of an early stage in the 
pathophysiology of type 2 diabetes10. 
Nondiabetic Glucose Disturbances and Acute 
Coronary Syndromes
Abnormalities in glucose control can be detected 
early after AMI and are strong risk factors for cardio-
vascular morbidity and mortality, even in nondiabetic 
patients. Usually, glucose disturbances are detected 
at hospital admission by routine blood glucose mea-
surement. While hypoglycemia is quite rare, hyperg-
lycemia occurs often. Hyperglycemia at admission is 
a common finding in diabetics with ACS and it is a 
consequence of transiently increased insulin resistance 
due to elevated levels of stress hormones and cytok-
ines, as shown in Figure 1. 
Hyperglycemia may also occur in patients without 
prior history of diabetes. In some, it is transient and 
may normalize in the following days (therefore called 
‘stress hyperglycemia’), but in others it is persistent re-
flecting the presence of diabetes mellitus11. 
Stress hyperglycemia is not an event exclusively 
specific for ACS. In almost all other states of acute 
illness, like in stroke, sepsis, etc., blood glucose levels 
my bee elevated12.
Surprisingly, despite the fact that stress hypergly-
cemia is a common event, it still lacks a widely ac-
cepted definition. Most authors consider hospital 
admission plasma glucose as a relevant finding, but 
the threshold value for stress induced elevated plasma 
glucose is still under dispute. However, most authors 
simply use definitions of non-stress hyperglycemia, 
according to ADA, WHO/IDF or EASD/ESC13, as 
shown in Table 1.
Stress hyperglycemia during critical illness has 
long been considered essential to provide fuel for vi-Fig. 1. Pathophysiological impact of hyperglycemia
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tal organs and hence was interpreted as a beneficial 
adaptation. Evidence is now growing against this no-
tion as hyperglycemia is identified as an independent 
risk factor for adverse outcome of numerous surgical 
and medical conditions, and avoiding hyperglycemia 
with intensive therapy has been shown to improve the 
outcome14-16. 
The association of higher glucose levels with mor-
tality in patients with unstable angina, NSTEMI and 
STEMI has been described, but not yet widely rec-
ognized.
Several studies have demonstrated hyperglycemia, 
with or without pre-existing diabetes mellitus, to be 
associated with adverse outcomes in patients with 
ACS, like death, recurrent myocardial infarction or 
heart failure. Stress hyperglycemia is associated with 
higher rates of infarction-related artery occlusion17. In 
patients who underwent primary percutaneous coro-
nary interventions (pPCI), the incidence of restenosis 
was higher in patients with blood glucose abnormali-
ties18,19. 
The underlying pathophysiology relating adverse 
clinical outcomes to hyperglycemia is unclear, and it 
is still uncertain whether increased plasma glucose is 
simply a marker of adverse outcomes or their cause. 
Endothelial dysfunction is characteristically seen 
in diabetes and in vivo studies have demonstrated that 
hyperglycemic spikes induce endothelial dysfunction 
in both normal and diabetic subjects. It is also known 
that acute glycemic excursions lead to a series of co-
agulation abnormalities likely to induce thrombosis. 
Atherosclerosis is now considered an inflammatory 
disease, and there are studies demonstrating that acute 
hyperglycemia can increase the production of highly 
sensitive C-reactive protein, plasma interleukin-6, in-
terleukin-18 and tumor necrosis factor-α20,21. 
One potential mechanism whereby hyperglycemia 
may mediate adverse clinical outcomes could be the 
adverse impact of hyperglycemia on platelet function. 
Increased platelet activation and aggregation occur in 
diabetic and acutely hyperglycemic patients due to in-
creased platelet degranulation, thromboxane synthe-
sis, impaired nitric oxide effect, and insensitivity to as-
pirin. Furthermore, deleterious changes in fibrinolysis 
and coagulation secondary to the metabolic derange-
ments of type 2 diabetes have emerged as the likely 
mechanisms underlying the increased cardiovascular 
risk. Plasminogen activator inhibitor-1 (PAI-1) is an 
inhibitor of the fibrinolytic system. Thus, elevated 
concentrations of PAI-1 promote persistence of clots 
and may have great impact on the prognosis in patients 
with ACS. Concentrations of PAI-1 are elevated in the 
blood and vessel walls of patients with type 2 diabetes 
or other insulin-resistant states22,23. Another possible 
mechanism leading to increased mortality in patients 
with stress hyperglycemia is its negative impact on left 
ventricular remodeling, as some echocardiographic 
studies have shown. Changes in end-diastolic volume, 
as well as in end-systolic volume were lesser in pa-
tients without stress hyperglycemia in the period up 
to one year after myocardial infarction. Decreased 
ejection fraction was more profound in patients with 
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higher levels of stress hyperglycemia. This finding can 
explain the larger proportion of heart failure in the 
group of patients with stress hyperglycemia8. 
A prolonged heart rate adjusted QT interval (QTc) 
has been shown to be predictive of sudden death and 
to correlate with measures of CAD. In a study looking 
at the effect of acute hyperglycemia induced by intra-
venous glucose load on the QTc interval, it was found 
that QTc and several sympathetic tone dependent he-
modynamic parameters were increased in response to 
this acute rise in glucose. This suggests that exagger-
ated glycemic surges, as seen in the postprandial state, 
can enhance the risk of sudden death in vulnerable 
persons by enhancing the sympathetic tone and pro-
longing the QTc interval9. 
The influence of stress hyperglycemia on mortality 
in patients with ACS seems to be independent even 
of the presence of previously diagnosed diabetes. El-
evated blood glucose levels at admission in patients 
with ACS were an important independent predictor 
of in-hospital mortality, even more important for pa-
tients without previously known diabetes, as reported 
in some studies24. 
It has to be commented that, compared with eug-
lycemic patients, those with stress hyperglycemia were 
older, with higher heart rates, prevalence of hyperten-
sion, congestive heart failure and diabetes, but less 
tobacco use25. 
According to some other papers, patients with pre-
viously known and well-controlled diabetes had simi-
lar rates of in-hospital adverse events to the patients 
without diabetes and without stress hyperglycemia26. 
While stress hyperglycemia seems to be recog-
nized as an important predictor of short-term, in-hos-
pital adverse events, fasting hyperglycemia and 
its impact on mortality has not been so often 
commented in the literature. 
However, the use of fasting blood glucose for 
risk stratification after AMI remains important. 
Fasting blood glucose after MI is particularly 
relevant because it also shows strong association 
with short-term prognosis after MI, as well as 
admission glycemia. Furthermore, even in non-
diabetic patients with AMI, fasting blood glu-
cose is an independent predictor of abnormal 
glucose tolerance as well as admission hypergly-
cemia27. 
Persistent hyperglycemia in comparison to both 
admission hyperglycemia and fasting hyperglycemia, 
perhaps has the strongest relation to early cardiovas-
cular events24. 
The Role of Hypoglycemia
Not only hyperglycemia, but also hypoglycemia 
is a harmful event for diabetics suffering from ACS, 
as evidenced most recently by the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial28. 
The intensive glucose lowering arm of this trial was 
stopped prematurely due to a higher rate of mortal-
ity in patients in the intensive arm versus those in the 
standard arm. However, there are some objections to 
this conclusion because the intensive glucose lower-
ing arm included more patients with a prior history of 
AMI and they were more often treated with rosigli-
tazone. In two similar trials, ADVANCE (Action in 
Diabetes and Vascular Disease) and VADT (Veterans 
Affairs Diabetes Trial)29, there was no benefit in the 
reduction of major cardiovascular events in the intense 
glucose lowering arms, probably due to the higher rate 
of hypoglycemia. In a smaller study, patients with hy-
poglycemia and ACS had lower body weight and were 
more often diabetic. 
The relationship of blood glucose and mortality 
seemed to be U-shaped among patients with ST-el-
evation myocardial infarction, with similar rates be-
tween patients with hypoglycemia and moderate hy-
perglycemia, as shown in Figure 228-31.
Fig. 2. Impact of admission glucose on short-term mortality 
in patients with acute myocardial infarction (adapted from 
Kosiborod et al.31).
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Treatment of Blood Glucose Disturbances in 
Acute Cardiac Patients
The management of glucose disturbances in acute 
states differs largely from common diabetic therapies 
in outpatients. 
The basic medications required for blood glucose 
regulation in all emergencies are short acting insu-
lins (or recently introduced ultra-short acting insu-
lin analogs), glucagon, crystalloid solutions of saline, 
glucose solution of different concentrations, and liq-
uid potassium salts. It is worth noting that all these 
medications should be applied parenterally, while oral 
administration of glucose lowering drugs, although 
theoretically possible, shows serious shortcomings. 
Sulfonylureas and related medications are not a good 
choice in emergencies due to the relatively slow onset 
of effects, and a relatively long half-life (for some of 
them, the effect lasts up to 24 hours). These drugs are 
also relatively less effective in states with a higher de-
gree of insulin resistance. Their performances are also 
not desirable in all intensive care units dealing with 
instable patients because of a relatively high risk of hy-
poglycemia. Medications like biguanides and thiazo-
lidinediones are contraindicated in heart failure. Fur-
thermore, some thiazolidinediones like rosiglitazone 
are withdrawn  because of the increased incidence of 
major adverse cardiovascular events. Administration 
of longer acting insulin and insulin analogs, as well 
as premixed insulin combinations is not contraindi-
cated, but may be less suitable for instable patients due 
to the long biological half-life of these insulin sub-
groups32-34. 
Special attention needs to be paid to adequate 
hydration and correction of electrolytic disorders in 
patients with hyperglycemia, which may be a thera-
peutic problem since the insufficient cardiac function 
may limit parenteral hydration34. 
It remains unclear, however, to what extent main-
taining normoglycemia and glycemia-independent ac-
tions of insulin account for the different clinical ben-
efits of intensive insulin therapy in the critically ill. 
Post hoc analyses of randomized controlled studies of 
intensive insulin therapy in surgical intensive care pa-
tients have suggested that blood glucose control best 
explains the clinical benefits of the intervention.
Several mechanisms may be involved in improv-
ing cardiovascular outcomes. The protective effect 
of insulin on the endothelium has been suggested 
to play a key role in the survival benefit of intensive 
insulin therapy. Endothelial protection is likely to 
improve microcirculation in vital organs, whereby 
their function may be protected and hence the risk of 
death reduced. Avoiding direct toxicity of glucose to 
endothelial cells, but perhaps also to other cells that 
take up glucose independently of insulin, such as neu-
rons and hepatocytes, may contribute to the survival 
benefit achieved with tight blood glucose control. The 
cardiovascular system appears to be crucially affected 
by intensive insulin therapy. It was demonstrated that 
high levels of insulin ameliorated myocardial contrac-
tility but only when normoglycemia was maintained 
concomitantly. This observation is of relevance to 
the controversy surrounding GIK (glucose + insulin 
+ potassium infusion) therapy. GIK traditionally fo-
cuses on insulin as the key component of a metabolic 
cocktail, which is thought to beneficially modulate 
myocardial metabolism. Insulin is thought to have di-
rect inotropic effect by economizing and ameliorating 
myocardial performance. In the DIGAMI (Diabetes 
Mellitus Insulin-Glucose Infusion in Acute Myocar-
dial Infarction)-1 study, GIK promoted survival of pa-
tients with diabetes and AMI. In this study, patients 
in the GIK arm had significantly lower blood glucose 
levels. However, after hospital discharge, there was no 
benefit shown for patients receiving intensive insulin 
therapy in comparison to patients given other thera-
pies (DIGAMI 2 study)30. 
Conclusion
Blood glucose levels should be routinely assessed 
among patients with ACS to possibly aid risk strati-
fication and tailoring of therapy. It seems that strict 
blood glucose control (glucose value should be close to 
the physiological values) is an imperative not only in 
the prevention but also in the treatment of ACS and 
prevention of reinfarction and heart failure. Finally, 
and perhaps most important of all, is the need for ACS 
patients with hyperglycemia to be properly evaluated 
for diabetes. Fasting glucose, HbA1c and glucose toler-
ance testing 2 hours after oral administration of 75 g 
glucose load are helpful investigations in identifying 
and treating the existing prediabetes or diabetes34. 
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Sažetak
POREMEćAJI METABOLIZMA GLUKOZE U BOLESNIKA S AKUTNIM KORONARNIM SINDROMOM
V. Altabas, K. Altabas, M. Berković-Cigrovski, S. Maloševac, M. Vrkljan i V. Nikolić Heitzler
Poremećaji metabolizma glukoze u akutnih bolesnika uključuju poremećaje poput hiperglikemije i hipoglikemije, od-
nosno odstupanja koncentracija glukoze u plazmi izvan referentnih raspona. Pritom je nevažno boluje li bolesnik od ranije 
dijagnosticirane šećerne bolesti. Hiperglikemija je česta kod ovakvih bolesnika zbog prolazno povišenih koncentracija 
kateholamina i kortizola, kao i niza proupalnih citokina, a može se javiti kod bolesti poput akutnog koronarnog sindroma, 
plućnog edema, plućne embolije, povreda, te teških infekcija i sepsa. Često se javlja kod bolesnika bez šećerne bolesti, kod 
dijabetičara može zahtijevati prolazno povišenje doza antidijabetičnih lijekova. Hipoglikemija se javlja mnogo rjeđe, po 
svom postanku je gotovo uvijek jatrogena. Hiperglikemija i hipoglikemija pogoršavaju prognozu akutnih bolesnika, te je u 
bolničkim uvjetima praćenje razine glukoze u krvi obvezno, uz uvođenje terapije kratkodjelujućim inzulinom kod hiper-
glikemije iznad 10 mmol/L. Dodatne informacije pruža određivanje acidobaznog statusa i ketona.
Ključne riječi: Akutni koronarni sindrom; Hiperglikemija; Hipoglikemija; Veći neželjeni kardiovaskularni ispadi

